Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
First Claim
1. A composition for delivery of indomethacin consisting of a condensation aerosol a. formed by volatilizing a coating of indomethacin on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of indomethacin and condensing the heated vapor of indomethacin to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% indomethacin degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention, an NSAID is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of an NSAID, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particle having less than 5% NSAID degradation products. In a kit aspect of the present invention, a kit for delivering an NSAID through an inhalation route is provided which comprises: a) a coating of an NSAID composition and b) a device for dispensing said coating as a condensation aerosol.
-
Citations
72 Claims
-
1. A composition for delivery of indomethacin consisting of a condensation aerosol
a. formed by volatilizing a coating of indomethacin on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of indomethacin and condensing the heated vapor of indomethacin to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% indomethacin degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
4. A composition for delivery of ketoprofen consisting of a condensation aerosol
a. formed by volatilizing a coating of ketoprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of ketoprofen and condensing the heated vapor of ketoprofen to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% ketoprofen degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
7. A composition for delivery of celecoxib consisting of a condensation aerosol
a. formed by volatilizing a coating of celecoxib on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of celecoxib and condensing the heated vapor of celecoxib to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% celecoxib degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
10. A composition for delivery of rofecoxib consisting of a condensation aerosol
a. formed by volatilizing a coating of rofecoxib on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of rofecoxib and condensing the heated vapor of rofecoxib to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% rofecoxib degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
13. A composition for delivery of meclofenamic acid consisting of a condensation aerosol
a. formed by volatilizing a coating of meclofenamic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of meclofenamic acid and condensing the heated vapor of meclofenamic acid to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% meclofenamic acid degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
16. A composition for delivery of fenoprofen consisting of a condensation aerosol
a. formed by volatilizing a coating of fenoprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of fenoprofen and condensing the heated vapor of fenoprofen to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% fenoprofen degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
19. A composition for delivery of diflunisal consisting of a condensation aerosol
a. formed by volatilizing a coating of diflunisal on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of diflunisal and condensing the heated vapor of diflunisal to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% diflunisal degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
22. A composition for delivery of naproxen consisting of a condensation aerosol
a. formed by volatilizing a coating of naproxen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of naproxen and condensing the heated vapor of naproxen to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% naproxen degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
25. A composition for delivery of ibuprofen consisting of a condensation aerosol
a. formed by volatilizing a coating of ibuprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of ibuprofen and condensing the heated vapor of ibuprofen to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% ibuprofen degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
28. A composition for delivery of flurbiprofen consisting of a condensation aerosol
a. formed by volatilizing a coating of flurbiprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of flurbiprofen and condensing the heated vapor of flurbiprofen to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% flurbiprofen degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
31. A composition for delivery of nabumetone consisting of a condensation aerosol
a. formed by volatilizing a coating of nabumetone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of nabumetone and condensing the heated vapor of nabumetone to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% nabumetone degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
34. A method of producing indomethacin in an aerosol form comprising:
-
a. heating a coating of indomethacin on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the indomethacin to form a heated vapor of the indomethacin, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the indomethacin comprising less than 5% indomethacin degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (35, 36)
-
-
37. A method of producing ketoprofen in an aerosol form comprising:
-
a. heating a coating of ketoprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the ketoprofen to form a heated vapor of the ketoprofen, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the ketoprofen comprising less than 5% ketoprofen degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (38, 39)
-
-
40. A method of producing celecoxib in an aerosol form comprising:
-
a. heating a coating of celecoxib on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the celecoxib to form a heated vapor of the celecoxib, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the celecoxib comprising less than 5% celecoxib degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (41, 42)
-
-
43. A method of producing rofecoxib in an aerosol form comprising:
-
a. heating a coating of rofecoxib on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the rofecoxib to form a heated vapor of the rofecoxib, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the rofecoxib comprising less than 5% rofecoxib degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (44, 45)
-
-
46. A method of producing meclofenamic acid in an aerosol form comprising:
-
a. heating a coating of meclofenamic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the meclofenamic acid to form a heated vapor of the meclofenamic acid, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the meclofenamic acid comprising less than 5% meclofenamic acid degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (47, 48)
-
-
49. A composition for delivery of tolfenamic acid consisting of a condensation aerosol
a. formed by volatilizing a coating of tolfenamic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of tolfenamic acid and condensing the heated vapor of tolfenamic acid to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% tolfenamic acid degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
52. A method of producing fenoprofen in an aerosol form comprising:
-
a. heating a coating of fenoprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the fenoprofen to form a heated vapor of the fenoprofen, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the fenoprofen comprising less than 5% fenoprofen degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (53, 54)
-
-
55. A method of producing diflunisal in an aerosol form comprising:
-
a. heating a coating of diflunisal on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the diflunisal to form a heated vapor of the diflunisal, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the diflunisal comprising less than 5% diflunisal degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (56, 57)
-
-
58. A method of producing tolfenamic acid in an aerosol form comprising:
-
a. heating a coating of tolfenamic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the tolfenamic acid to form a heated vapor of the tolfenamic acid, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the tolfenamic acid comprising less than 5% tolfenamic acid degradation products, and an aerosol having an MMAD of less than 3 microns.
-
-
59. The method according to claim 59, wherein the aerosol particles are formed at a rate of greater than 109 particles per second.
-
60. The method according to claim 60, wherein the aerosol particles are formed at a rate of greater than 1010 particles per second.
-
61. A method of producing naproxen in an aerosol form comprising:
-
a. heating a coating of naproxen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the naproxen to form a heated vapor of the naproxen, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the naproxen comprising less than 5% naproxen degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (62, 63)
-
-
64. A method of producing ibuprofen in an aerosol form comprising:
-
a. heating a coating of ibuprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the ibuprofen to form a heated vapor of the ibuprofen, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the ibuprofen comprising less than 5% ibuprofen degradation products, and an aerosol having an MMAD of less than 3 microns.
-
- 65. The method according to claim 65, wherein the aerosol particles are formed at a rate of greater than 109 particles per second.
-
67. A method of producing flurbiprofen in an aerosol form comprising:
-
a. heating a coating of flurbiprofen on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the flurbiprofen to form a heated vapor of the flurbiprofen, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the flurbiprofen comprising less than 5% flurbiprofen degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (68)
-
-
69. The method according to claim 69, wherein the aerosol particles are formed at a rate of greater than 1010 particles per second.
-
70. A method of producing nabumetone in an aerosol form comprising:
-
a. heating a coating of nabumetone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the nabumetone to form a heated vapor of the nabumetone, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the nabumetone comprising less than 5% nabumetone degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (71, 72)
-
Specification